Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study
- 15 March 2002
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 99 (6) , 1938-1942
- https://doi.org/10.1182/blood.v99.6.1938
Abstract
In a prospective cohort study, we assessed the incidence of spontaneous and risk period–related venous thromboembolism (VTE) in asymptomatic family members of patients who experienced VTE and had the factor V Leiden mutation. In all, 561 family members of 131 probands were included, 313 of whom were carriers (299 heterozygous and 14 homozygous) and 248 of whom were noncarriers of the factor V Leiden mutation. Average follow-up was 4 years (range, 4 months-6 years). There were 1255 and 984 observation-years of follow-up in carriers and noncarriers, respectively. Eight episodes of VTE occurred in heterozygous carriers, resulting in an annual incidence of 0.67% (95% confidence interval [CI], 0.29-1.33). Two events occurred in the absence of associated risk factors, determining an annual incidence of spontaneous VTE of 0.17% (95% CI, 0.02-0.6). Only one VTE (risk period–related) occurred in noncarriers, with an annual incidence of 0.1% (95% CI, 0.003-0.56). Relative risk for VTE in heterozygous carriers compared with noncarriers of the factor V Leiden mutation was 6.6 (95% CI, 1.1-39.8). Risk period–related VTE occurred with an incidence of 18% and 5% per risk period in heterozygous carriers and in noncarriers, respectively. Thus, the low rate of VTE in asymptomatic family members carrying the mutation did not justify continuous anticoagulant prophylaxis. Screening families of symptomatic probands with the factor V Leiden mutation has the potential to identify those asymptomatic carriers who might benefit from thromboprophylaxis during risk periods.Keywords
This publication has 24 references indexed in Scilit:
- Prothrombin and Factor V Mutations in Women with a History of Thrombosis during Pregnancy and the PuerperiumNew England Journal of Medicine, 2000
- A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous ThromboembolismNew England Journal of Medicine, 1999
- Additional genetic risk factors for venous thromboembolismin carriers of the factor V Leiden mutationBritish Journal of Haematology, 1998
- Homozygous patients with APC resistance may remain paucisymptomatic or asymptomatic during oral contraceptionBlood Coagulation & Fibrinolysis, 1996
- Prevalence of Antiphospholipid Antibodies and Lupus Anticoagulant in Juvenile Patients with Objectively Documented Deep-vein ThrombosisClinical and Applied Thrombosis/hemostasis, 1996
- Noninvasive Objective Tests for the Diagnosis of Clinically Suspected Deep-Vein ThrombosisPathophysiology of Haemostasis and Thrombosis, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Resistance to Activated Protein C as a Basis for Venous ThrombosisNew England Journal of Medicine, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- A prospective study of the incidence of deep‐vein thrombosis within a defined urban populationJournal of Internal Medicine, 1992